Immutep Limited (FRA:YP1B)

Market Cap	349.36M +23.2%
Revenue (ttm)	2.82M +31.3%
Net Income	-34.30M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.2160
Previous Close	0.2180
Day's Range	0.2160 - 0.2160
52-Week Range	0.1080 - 0.2500
Beta	n/a
RSI	51.09
Earnings Date	Feb 22, 2026

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YP1B

Financial Performance

In fiscal year 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD